Biofil Chemicals & Pharmaceuticals Limited Stock Price Today (NSE: BIOFILCHEM)

Biofil Chemicals & Pharmaceuticals Limited

BIOFILCHEMPharmaceuticals
33.130.52 (1.55%)
Market Closed

Fundamental Score

...

Biofil Chemicals & Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Biofil Chemicals & Pharmaceuticals Limited share price today is 33.13, down 1.55% on NSE/BSE as of 16 September 2026. Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 53.92 (Cr). The 52-week high for BIOFILCHEM share price is 46.34 and the 52-week low is 25.60. At a P/E ratio of 110.43x, BIOFILCHEM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.81% and a debt-to-equity ratio of 0.14.

Biofil Chemicals & Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
34.68
Low
30.12
Volume
65.1K
Change
-3.43%

Biofil Chemicals & Pharmaceuticals Limited share price chart: -3.43% return over the past month. 52-week high ₹46.34, 52-week low ₹25.60.

Biofil Chemicals & Pharmaceuticals Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
33.0033.7133.0033.1311.77K (Cr)
34.4035.4933.1033.6533.48K (Cr)
37.8037.8032.3634.511.73L (Cr)
31.4637.7531.4636.796.82L (Cr)
32.1532.1531.2631.467.17K (Cr)
32.7032.7031.5031.5212.62K (Cr)
31.3632.7031.3632.046.96K (Cr)
32.8032.8031.3132.005.54K (Cr)
32.1032.6831.7131.9723.21K (Cr)
32.6032.8031.5531.954.88K (Cr)

Biofil Chemicals & Pharmaceuticals Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
32.9037.8031.2633.13+0.70%
32.0534.6830.1232.59+1.68%
35.8535.8531.6131.94-10.91%
35.0939.0033.1134.94-0.43%
33.1039.9931.1035.09+6.01%
26.6936.3026.5134.05+27.58%
30.5132.2525.6025.79-15.47%
39.0046.3431.2532.04-17.85%
33.9238.4028.5029.26-13.74%
37.2038.2532.5233.57-9.76%
39.5040.7435.5037.23-5.75%
40.7243.4738.0039.74-2.41%

Returns & Performance

Poor

Return on Equity (ROE)

13.81%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

16.77%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

3.79%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Biofil Chemicals & Pharmaceuticals Limited Valuation Check

Poor

Price to Earnings (P/E)

110.43x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

46.79%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.08%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-95.47%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

91.99%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-4.50%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

17.61%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

17.46%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.14x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

342.54x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-0.87 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Biofil Chemicals & Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of BIOFILCHEM across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Excellent ROCE Performance (16.77%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Revenue Growth (91.99%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Excellent EPS Growth (17.61% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (17.46% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.14)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (342.54x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Margin Pressure Concerns (3.79%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Premium Valuation Risk (P/E: 110.43x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-95.47%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Growth History (-4.50% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Negative Free Cash Flow (₹-0.87 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.08%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Biofil Chemicals & Pharmaceuticals Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Biofil Chemicals & Pharmaceuticals Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
44.2/100
33
₹53.92
110.4
Average
13.81%
Average
16.77%
Good
0.1
Excellent
17.46%
Excellent
-4.50%
Poor
0.00%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9426
₹249775.75
85.5
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4927
₹166759.24
78.7
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1370
₹110675.45
32.8
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1926
₹104025.14
95.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1675
₹96391.01
26.2
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96017.92
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1141
₹95306.90
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2289
₹94539.83
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Biofil Chemicals & Pharmaceuticals Limited PE Ratio History

Historical price-to-earnings ratio for BIOFILCHEM — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20240.44₹57.45130.6x
FY 20230.34₹54.15159.3x
FY 20220.44₹55.20125.5x
FY 20210.77₹62.3581x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Biofil Chemicals & Pharmaceuticals Limited Quarterly Performance

Latest quarterly metrics for BIOFILCHEM — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

91.99%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-95.47%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-4.50%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

17.46%

Compounded annual net profit growth over 5 years

Biofil Chemicals & Pharmaceuticals Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for BIOFILCHEM — calculated from daily price history

56RSI 14
Neutral — RSI 56

Momentum is balanced — neither overbought nor oversold.

SMA 50
33
▲ Price above SMA 50 — Short-term bullish
SMA 200
33
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
50K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Biofil Chemicals & Pharmaceuticals Limited Financial Statements

Annual income statement, balance sheet and cash flow for Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Biofil Chemicals & Pharmaceuticals Limited

Loading latest quarterly results...

About BIOFILCHEM (Biofil Chemicals & Pharmaceuticals Limited)

Biofil Chemicals & Pharmaceuticals Ltd is a dynamic and innovative pharmaceutical company dedicated to advancing healthcare solutions. The company operates with a commitment to qua...lity, safety, and efficacy in the development, manufacturing, and distribution of a diverse range of pharmaceutical products. Biofilchem's core focus lies in addressing unmet medical needs and improving patient outcomes through cutting-edge research and development. Their state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring that every product meets the highest level of excellence. They are driven by a team of experienced professionals and scientists, dedicated to discovering, developing, and delivering innovative therapies that make a meaningful difference in people's lives. Biofilchem is committed to ethical business practices and environmental sustainability, reflecting their responsibility towards society. Biofilchem stands as a multifaceted pharmaceutical entity, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. Their expertise extends to the intricate synthesis of essential drug components and the formulation of safe and effective medications. They have built a reputation for providing high-quality, affordable medicines across various therapeutic areas, including but not limited to anti-infectives, cardiovascular, and central nervous system treatments. Beyond in-house production, Biofilchem actively collaborates with other pharmaceutical companies, offering contract manufacturing services that leverage their advanced facilities and regulatory expertise. This collaborative approach allows them to contribute to the broader healthcare ecosystem, ensuring a reliable supply of quality medications to meet growing demands. At the heart of Biofilchem's philosophy is a patient-centric approach, driving them to constantly innovate and improve their product offerings. They strive to understand the evolving needs of healthcare providers and patients, focusing on developing user-friendly formulations and convenient dosage forms. The company invests significantly in research and development, exploring novel drug delivery systems and developing generic versions of essential medicines. This commitment to innovation ensures access to affordable healthcare for a wider population. Biofilchem's dedication to quality, innovation, and ethical practices positions them as a trusted partner in the pharmaceutical industry, contributing to a healthier future for all.

Company Details

Symbol:BIOFILCHEM
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Ketan Shah
MD & Chairman
Mr. Pavan Singh Rajput
Chief Financial Officer
Joseph Chacko
Head of Administration

BIOFILCHEM Share Price: Frequently Asked Questions

What is the current share price of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) trades at ₹33.13 on NSE and BSE. Market cap ₹53.92 (Cr). Educational data only.

What is the P/E ratio of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has a P/E of 110.43x vs industry average 34.89x.

What is the Bull Run score for Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has a Bull Run score of 44.2/100 based on 25+ financial parameters.

Does Biofil Chemicals & Pharmaceuticals Limited pay dividends?

Biofil Chemicals & Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has ROE of 13.81%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has debt-to-equity of 0.14.

Is Biofil Chemicals & Pharmaceuticals Limited a good investment?

Bull Run gives Biofil Chemicals & Pharmaceuticals Limited a score of 44.2/100. This is not investment advice — consult a SEBI-registered advisor.